Slides
Page 1
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview February 2026 1
Page 2
2 © 2026, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the acceptance by the market of our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our iCTC facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial launch; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with regulatory authorities may support registrational studies and subsequent approvals by regulatory authorities, including the r isk that the planned registrational trial in advanced sarcomas may not support approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or c ohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of a uthorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this presentation assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this presentation; and no material fluctuation in exchange rates.
Page 3
3 © 2026, Iovance Biotherapeutics, Inc. Global Leadership in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer 3 Approved Products Commercial Launch Financials >85 ~$303M Cash as of 12/31/25 Treatment Centers as of 12/31/25* 2 ~95% 50% Gross Margin (Q4 2025) © 2026, Iovance Biotherapeutics, Inc. *Includes centers in final stages of readiness or soon to be authorized. Abbreviations: FDA, U.S. Food and Drug Administration >1,500 Patients treated with commercial and clinical Iovance TIL products U.S. & Canada Multiple Markets Globally ~30% Full Year 2025 Revenue $264M (Guidance of $250M-$300M Achieved) Addressable Patients within 200 miles of an ATC Q4 2025 Quarterly Revenue Growth
Page 4
4 © 2026, Iovance Biotherapeutics, Inc. The Pioneer in One-Time Cell Therapy for Solid Tumors 4 4 © 2026, Iovance Biotherapeutics, Inc. 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre-Treated Patient Population; 2. Karapetyan et al, Tandem Meeting 2026. Physician-assessed confirmed ORR by RECIST v1.1. All evaluable patients received commercial Amtagvi according to the U.S. prescribing information; 3. Interim data cut as of October 10, 2025 of patients with nonsquamous NSCLC with minimum cell dose based on FDA feedback for melnaoma. Patients progressed on or after chemotherapy and anti -PD-1 therapy for mNSCLC without EGFR, ROS1 or ALK genomic mutations and received at least one line of FDA -approved targeted therapy if indicated by other actionable tumor mutations; 4. As of December 31, 2025 *Nonsquamous mNSCLC without EGFR, ROS1 or ALK genomic mutations Abbreviations: 2L, second line; FTD, fast track designation; mDOR, median duration of response; mNSCLC, metastatic non -small cell lung cancer; OpEx, operating expenses; ORR, objective response rate; mOS, median overall survival; SOC, standard of care Platform technology and robust pipeline in blockbuster solid tumor indications $1B+ U.S. Sales Potential in 2L+ Advanced Melanoma ~7X U.S. Melanoma Opportunity in 2L mNSCLC* Operational Excellence Focused on Profitability • First and only approved treatment in 2L+ advanced melanoma • ~30% quarterly growth in 4Q25 • ~$264M total revenue in first calendar year of launch • 5-year durability: 34% ORR; ~20%OS; mDOR of >36 months1 • Real-world ~44% ORR; 52% ORR in patients with≤ 2 prior lines of therapy2 • High unmet need with limited treatment options • SOC: ~13% ORR; ~8 months mDOR; ~13 months mOS • Potential best-in-class lifileucel clinical profile: ~26% ORR; mDOR not reached at 25+ months follow up3 • FTD for NSCLC from U.S. FDA • Potential launch in 2H27 • Leverages melanomacommercial footprint and manufacturing • $303M cash4 runway into 3Q27 • 50% gross margin (4Q25) • Ongoing initiatives improving OpEx, cost of sales and gross margin • Leading IO pipeline in solid tumors • Internal manufacturing • 5K+ annual capacity for North America, Europe & APAC • 1.5K+ commercial and clinical patients treated
Page 5
5 © 2026, Iovance Biotherapeutics, Inc. Strong Platform Supports Backbone IO Therapy for Solid Tumors Iovance Retains Global Portfolio and Technology PlatformRights Approved Amtagvi Treatment RegimenCanada EU: Updated Submission Planned Australia 1H26 Switzerland 1H27 UK 1H26 U.S. Under Review Additional Clinical & Commercial UseCanada U.S. *Planned to commence in 2026 Abbreviations: 2L, second line; 4L, fourth line; DDLPS, dedifferentiated liposarcoma; FTD, Fast Track Designation; IO, immuno -oncology; IL-2, interleukin 2; IL-12, interleukin 12; NSCLC, non-small cell lung cancer; PD -1, programmed cell death protein-1; UPS, undifferentiated pleomorphic sarcoma INDICATION & TREATMENT SETTING PHASE 1 PHASE 2 PHASE 3 Registration- Directed Lifileucel + pembrolizumab Frontline advanced melanoma TILVANCE-301 (FTD, Confirmatory) Lifileucel Post-chemo & anti-PD-1 advanced NSCLC IOV-LUN-202 (FTD) Lifleucel Post-chemo advanced soft tissue sarcomas (DDLPS or UPS) IOV-SAR-201* Lifileucel Pipeline Lifileucel Post anti-PD-1 advanced melanoma IOV-MEL-202 Lifileucel Post-chemo & anti-PD-1 endometrial cancer IOV-END-201 Next- Generation Products PD-1 Inactivated TIL (IOV-4001) Post anti-PD-1 advanced melanoma or NSCLC IOV-GM1-201 IL-2 analog (IOV-3001) TIL treatment regimen IOV-IL2-101 IL-12 tethered TIL (IOV-5001) Basket trial IOV-GE1-201*
Page 6
6 © 2026, Iovance Biotherapeutics, Inc. Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors Unique Mechanism of Action • Individualized • One-time therapy • Patient’s T cells fight cancer Tumor Tissue Collection Patient-specific T Cells Grown into the Billions 1 TIL Treatment Regimen 1. Amtagvi USPI
Page 7
7 © 2026, Iovance Biotherapeutics, Inc. U.S. Deaths1 Global Deaths2 Melanoma 8K 59K Lung & Bronchus 125K 1.8M Soft Tissue Sarcomas 5K 50K Endometrial 13K 97K 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. https://seer.cancer.g ov (accessed February 2026) 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022; Zhou et al. BMC Public Health 2025 91% of all cancer cases are solid tumors1 Market Expansion Opportunity in Solid Tumors 1 New indications: 2 Additional markets: Amtagvi® Approved Markets Planned Markets
Page 8
8 © 2026, Iovance Biotherapeutics, Inc. 8 First FDA-approved One-time, Individualized T cell Therapy for a Solid Tumor Cancer
Page 9
9 © 2026, Iovance Biotherapeutics, Inc. Significant unmet need in frontline and beyond1 Advanced Melanoma Market Opportunity 2L+ Advanced Melanoma Population 2,3 US: 8K Potential ex-US Markets: 22K Overall (1L+): 70K BRAF wild-type (prior ICI therapy) ~5 months BRAF mutated (prior ICI and targeted therapy) ~3 months 1. Chesney J, et al. J Immunother Cancer. 2022; 2. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. https:/ /seer.cancer.gov (accessed August 2025); World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022;3. Data on file as of July 2025. Includes more than 20,000 patients initial target markets plus additional potential markets; 4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. NEJM. 5. Robert C, et al.. Lancet 6. Tawbi HA, Schadendorf D, Lipson EJ, et al. NEJM 7. Patrinely JR et al.Cancer.2020 Abbreviations: 1L, first line; ICI, immune checkpoint inhibitors; mOS, median overall survival; mPFS, median progression-free survival; PD-(L)1, programmed death receptor-1 or programmed death-ligand >50% of patients on 1L standard of care progress within 12 months4-6 mOS after Progression on 1L Therapy:7
Page 10
10 © 2026, Iovance Biotherapeutics, Inc. One Third of Responses Remain Ongoing without Subsequent Treatment 5 Year OS 19.7% mDOR 36.5 MonthsORR 31.4% mOS 13.9 Months 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre-Treated Patient Population Abbreviations: mDOR, median duration of response; mOS, media overall survival; NR, not reached; ORR, objective response rate Duration of Response Overall Survival Deep and Durable Responses at 5-Year Follow Up1 A M T A G V I ® I N P R E V I O U S L Y T R E A T E D A D V A N C E D M E L A N O M A Median Follow Up 57.8 Months
Page 11
11 © 2026, Iovance Biotherapeutics, Inc. 52% ORR (12/23) Best-in-class real-world data driving increased Amtagvi adoption1 A M T A G V I ® I N P R E V I O U S L Y T R E A T E D A D V A N C E D M E L A N O M A 1. Karapetyan L et al. Tandem Meetings 2026. 2. Three Prior Lines of Therapy (1L-3L): 1L ipilimumab + nivolumab; 2L dabrafenib + trametinib; 3L nivolumab + relatlimab. 86% reduction in target lesions. Response ongoing at 260-day follow up. Photo Credit and Permission: H. Lee Moffitt Cancer Center Abbreviations: DCR, disease control rate; ORR, objective response rate 44% ORR ( 1 8 / 4 1 ) 33% ORR (6/18) Before Lifileucel Post-Lifileucel (Week 6) Durable Ongoing Partial Response (PR)2 Significant tumor burden reduction at Week 6 ≤ 2 prior lines of therapy ≥ 3 prior lines of therapy Unprecedented Real-World Response Rates Presented at 2026 Tandem Meetings 73% DCR (3 0 / 4 1 ) Higher Response Rates with Earlier Treatment
Page 12
12 © 2026, Iovance Biotherapeutics, Inc. 12 © 2026, Iovance Biotherapeutics, Inc. Lymphodepletion Reimbursement ~3 Weeks Manufacturing, Release & Shipment Short-Course Proleukin® Scheduling Goal: <2 weeks Primary Oncologist ATC Medical Oncologist Follow-Up & Return to Primary Oncologist ENROLLMENT 3-4 WEEKS ~32 DAYS Community Practice Amtagvi® Patient Journey A M T A G V I ® I N P R E V I O U S L Y T R E A T E D A D V A N C E D M E L A N O M A Amtagvi® TREATM ENT REGIMEN Broad payer coverage consistent with Amtagvi label, clinical trials and NCCN guidelines
Page 13
13 © 2026, Iovance Biotherapeutics, Inc. • Modular design • Global supply and logistics • Capacity for up to 5K patients/year • Optimal utilization, quality & COS Manufacturing Facility Dedicated to Commercial and Clinical TIL Cell Therapies COS = cost of sales Philadelphia, PA
Page 14
14 © 2026, Iovance Biotherapeutics, Inc. Amtagvi® Authorized Treatment Centers (ATC) A M T A G V I ® I N P R E V I O U S L Y T R E A T E D A D V A N C E D M E L A N O M A 10K+≤100 Population2 1. Not all authorized treatment centers are listed, Includes onboarded ATCs as well as in -process ATCs. 2. U.S. Census Bureau, 2024 Annual Estimates. SEER annual estimated death rate from melanoma: 2 deaths per 100K people: https://seer.cancer.gov/ (accessed April 2025) 3. Internal data
Page 15
15 © 2026, Iovance Biotherapeutics, Inc. Broad Market Access Data on file as of July 2025. *Plans or policies that cover Amtagvi, including pharmacy benefit managers (PBMs) Abbreviations: NCCN, National Comprehensive Cancer Network Payer medical coverage policies consistent with Amtagvi label, clinical trials and NCCN guidelines Patient lives covered; Majority of patients have private coverage* Typical time to financial clearance 250+ Million ~3 Weeks >75% of Amtagvi patients covered by private payers
Page 16
16 © 2026, Iovance Biotherapeutics, Inc. 16 Amtagvi® Expansion Plans in Advanced Melanoma
Page 17
17 © 2026, Iovance Biotherapeutics, Inc. Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma • Median PFS and median DOR not reached at nearly 2 years of median follow-up (median follow-up 21.7 months) • All response-evaluable patients demonstrated regression of target lesions • Safety consistent with underlying disease and known safety profiles of pembrolizumab, NMA-LD, lifileucel, and IL-2 • Late AEs consistent with anti-PD-1 monotherapy, differentiated from ICI combination therapies L I F I L E U C E L + P E M B R O L I Z U M A B I N F R O N T L I N E A D V A N C E D M E L A N O M A : I O V- C O M- 2 0 2 C O H O R T 1 A 1. Thomas et al, ASCO 2024; Data on file as of May 31, 2024. *Unconfirmed CRs, confirmed following data cut. aOne patient without a postdose tumor response assessment was not included. bTarget lesion lymph node at baseline decreased by 50% is no longer pathological, and thus is shown here as -100% representing uCR. Abbreviations: CI, confidence interval; CR, complete response; DOR, duration of response; ICI, immune checkpoint inhibitor; O RR, objective response rate; PD, progressive disease; PFS, progression free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SOD, sum of diameters; AE, adverse event; IL-2, interleukin-2; NMA-LD, nonmyeloablative lymphodepletion Data support rationale for TILVANCE frontline study:1 65.2% ORR via RECIST v 1.1 30.4% CR 64.7% PFS at 6 & 12 months Best Percentage Change from Baseline in Target Lesion SOD Time to Response and Time of Efficacy Assessment for Confirmed Responders (PR or Better)
Page 18
18 © 2026, Iovance Biotherapeutics, Inc. Option to crossover to lifileucel after BIRC-confirmed PD 1:1 Randomization TILVANCE-301 Global Phase 3 and Confirmatory Trial L I F I L E U C E L + P E M B R O L I Z U M A B I N F R O N T L I N E A D V A N C E D M E L A N O M A *Pembrolizumab in both arms is started at the same time after randomization. Abbreviations: BIRC, blinded independent review committee; ORR, objective response rate; PD, progressive disease; PD -1, programmed cell death protein-1; PFS, progression free survival Arm A: lifileucel plus pembrolizumab* Long-term follow up Patient Population Unresectable or metastatic melanoma; no prior therapy for metastatic disease N=670 75+ sites in U.S., Canada, Europe, APAC Arm B: pembrolizumab alone* Study Design with FDA Agreement • Dual primary endpoints: ORR & PFS • Interim analysis on ORR • Finalanalysis on PFS • Registrational for frontline melanoma • Confirmatory for full approval of Amtagvi® in post-anti-PD-1 melanoma • Enrollment on track with internal projections Randomized, multicenter study with optionalcrossover to Iifileucel (NCT05727904)
Page 19
19 © 2026, Iovance Biotherapeutics, Inc. 19 TIL Therapy Pipeline
Page 20
20 © 2026, Iovance Biotherapeutics, Inc. 1M+ Global Annual Deaths1 Significant Unmet Need in 2L Nonsquamous NSCLC – Limited durability with SOC Chemo (Docetaxel)2 5.6 mo mDOR 12.3 mo OS 12.8% ORR >90K Annual Deaths1 1. Data on file as of November 2025, includes targeted patient population in potential future commercial markets. 2. Ahn MJ et al. J Clin Onc 2024;43:260-272. Abbreviations: APAC, Asia Pacific; mDOR, median duration of response; mo, month; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; SOC, standard of care >150K Annual Deaths1 >75K Annual Deaths1 TIL Experience is Growing at Leading Cancer Centers across North America, Europe & APAC Global NSCLC Commercial Opportunity ~7X Current Melanoma Opportunity1
Page 21
21 © 2026, Iovance Biotherapeutics, Inc. IOV-LUN-202 Registrational Trial Design Phase 2 Multicenter Study of Lifileucel in Post-Anti-PD-1 NSCLC (NCT04614103) Abbreviations: Anti-PD-1, anti-programmed cell death inhibitor; IRC, independent review committee; NSCLC, non -small cell lung cancer; ORR, objective response rate; TPS, tumor proportion score Iovance TIL Therapy Lifileucel in NSCLC IOV-LUN-202 is designed to enroll patients with advanced NSCLC post anti-PD-1 treatment Endpoints • Primary: ORR by IRC • Secondary: Safety Patient Population Unresectable or metastatic NSCLC with progression on or after prior anti-PD-1 treatment and chemotherapy 65+ sites in U.S., Canada, Europe, APAC Cohort 1: < 1% or unknown TPS Cohort 2: ≥ 1% TPS Registrational Cohorts
Page 22
22 © 2026, Iovance Biotherapeutics, Inc. Fast Track Designation in Second-Line Nonsquamous mNSCLC I O V- L U N- 2 0 2 C O H O R T S 1 & 2 P O S T- A N T I- PD - 1 A D V A N C E D N S C L C 1.Interim data cut as of October 10, 2025 of patients with nonsquamous NSCLC with minimum cell dose based on FDA feedback in me lanoma. Patients progressed on or after chemotherapy and anti -PD-1 therapy for mNSCLC without EGFR, ROS1 or ALK genomic mutations and received at least one line of FDA -approved targeted therapy if indicated by other actionable tumor mutatio ns. 2. Time to response, time on assessment for confirmed responders (PR or better). A bar is presented for each patient starting from date of lifileucel infusion up to date of new anti-cancer therapy, end of assessment, death, or data cutoff date, whichever occurs earlier. *Patient 23 in ongoing follow up to confirm PR. Abbreviations: CR, complete response; mNSCLC, metastatic non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; uPR, unconfirmed partial response One-Time Therapy with Unprecedented Durability and Potential Best-in-Class Clinical Profile1 25.6% ORR (n=39; RECIST 1.1) mDOR Not Reached (Median follow up: 25.4 months) Patients Time (months) Since Lifileucel Infusion % Change From Baseline Durability of Response2 Patients Best Percentage Change from Baseline in Target Lesion(s)
Page 23
23 © 2026, Iovance Biotherapeutics, Inc. Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC1 I O V- C O M- 2 0 2 C O H O R T 3 A , I C I- N A Ï V E N S C L C % Change from Baseline Time (Months) Since TIL Infusion PD-L1 negative, EGFRWT subgroup has a high unmet need2 Best Percentage Change from Baseline in Target Lesion SOD 64.3% ORR EGFRWT Time to Response for Confirmed Responders (PR or Better, EGFRWT Patients) mDOR not reached (median follow-up 26.5 months) • Safety consistent with Iovance TIL combination studies • Supports adding TIL therapy to pembrolizumab plus chemotherapy for frontline NSCLC in IOV-COM-202 cohorts 3D/3E 1. Creelan et al,SITC 2024 2. KEYTRUDA USPI; OPDIVO USPI *PR response based on target lesion reduction of 100% with the persistence of nontarget lesions. Abbreviations: CR, complete response; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; NSCLC, non -small-cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SOD, sum of diameter; TPS, tumor proportion score; WT, wild -type 54.5% ORR EGFR WT PD-L1 Negative by RECIST 1.1 Anti-PD-1 ORR Benchmarks2 Treatment-naïve (mono) 27% (TPS ≥ 1%); 39 - 45% (TPS ≥ 50%) Post-chemotherapy (mono) 18 - 20% Frontline (anti-PD-1 + chemo) 48-58% 2 Patients 60 40 20 0 –20 –40 –60 –80 –100 a 3A-03 3A-16 3A-08 3A-22 3A-15 3A-09 3A-04 3A-02 3A- PD-L1 TPS <1 <1 <1 <1 ≥50 <1 <1 <1 <1 3A-10 ≥50 3A-17 ≥50 3A-11 <1 3A-13 <1 80 100 PD SD PR CR
Page 24
24 © 2026, Iovance Biotherapeutics, Inc. 1.. CancerMPact Patient Metrics for US Soft Tissue Sarcoma (accessed February 2026); 2. Zhou et al. BMC Public Health 2025; 3. CancerMPact Treatment Architecture for Sarcoma for the US & EU5 (May 2025) to inform treatment rates in the US and EU5. 4. Parikh RC, et al. Cancer. 2018. 5. Italiano A, et al. Ann Oncol. 2012; 6. Jones RL et al. Ann Oncol. 2023. Abbreviations: 2L, second line; DDLPS, dedifferentiated liposarcoma; DCR, disease control rate; ICI, immune checkpoint inhibitor; ORR, objective response rat e; RECIST, Response Evaluation Criteria in Solid Tumors; SOD, sum of diameter (in millimeters); UPS, undifferentiated pleomorphic sarcoma Significant Market Opportunity for Advanced Tissue Sarcomas L I F I L E U C E L I N A D V A N C E D S O F T T I S S U E S A R C O M A S Practice-changing potential in rare, high grade, aggressive refractory UPS & DDLPS with very high unmet need Deep responses improved over time • All evaluable patients had significant disease burden • Safety consistent with lifileucel in other indications Current 2L SOC has low ORR (<5%) with short durability4-6 • No approved ICI options Phase 2 registrational trial to commence in 2Q 2026 • Targeting expedited pathways for registration • Plan to explore additional high grade soft tissue sarcoma subtypes >3K >5K US annual cases1 Patients with advanced disease3 Europe annual cases2 >3.5K >8K Patients/yr (US & Europe) 50% ORR via RECIST v1.1 2.33 Mean Prior Lines of Therapy 117 mm Baseline Mean SOD
Page 25
25 © 2026, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. https://seer.cancer.gov (accessed August 2025); 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022; 3. NCCN Guidelines Version 2.2024 Endometrial Carcinoma; 4. Kang et al, Nature Portfolio, Scientific Reports, 2022; 5. Makker V, et al. N Engl J Med. 2022; 6. McMeekin S, et al. Gynecol Oncol. 2015. Abbreviations: Anti-PD-1, anti-programmed cell death inhibitor; pMMR , proficient DNA mismatch repair; dMMR , deficient DNA mismatch repair; SOC, standard of care; TMB-H, tumor mutational burden high; ORR, objective response rate Potential Market for Advanced Endometrial Cancer L I F I L E U C E L I N A D V A N C E D E N D O M E T R I A L C A N C E R Immunosensitive Tumor Type with Significant Unmet Need in 2L+ Anti-PD-(L)1 moving into front-line therapy setting3 No standard of care for 2L+ post-anti-PD-1 • Molecularly defined subgroups with available targeted therapies are small • ORR with mono-chemotherapy after front-line chemo doublet: ~15%5,6 • Limited data on treatments after anti-PD-(L)1 ~14K ~98K US annual uterine cancer deaths 1 5-yr survival (distant metastases)1 Global deaths2 19.5% Endometrial Cancer Biomarkers4 dMMR: 27% pMMR: 73% >90% of Uterine Cancers are Endometrial
Page 26
26 © 2026, Iovance Biotherapeutics, Inc. pMMR Subgroup dMMR Subgroup Endpoints • Primary: ORR per RECIST v1.1by investigator • Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability • Subgroup analyses specified in protocol • Potential to expand / convert to registrational trial • First patient enrolled Q4 2024 IOV-END-201 Phase 2 Proof of Concept Study Endometrial Cancer Patient Population* Recurrent, metastatic or primary unresectable disease after chemo and anti-PD-1 therapy ≤3 lines of prior systemic therapy with no more than 1 line of chemotherapy *Sample size and study population of registrational ph2 study will be determined after PoC final analysis Abbreviations: Anti-PD-1, anti-programmed cell death inhibitor; CR, complete response; dMMR, mismatch repair deficient; pMMR, mi smatch repair proficient; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival L I F I L E U C E L I N A D V A N C E D E N D O M E T R I A L C A N C E R Proof-of-Concept Trial in Patients with Mismatch Repair (MMR) Proficient and Deficient Tumors (NCT06481592)
Page 27
27 © 2026, Iovance Biotherapeutics, Inc. 27 © 2026, Iovance Biotherapeutics, Inc. IOV-4001: PD-1 Inactivated TIL Therapy 2 T cell PD-1 PD-1 inhibits the ability of T cells to fight cancer: T cells, upon encountering cancer cells, produce PD-1, a checkpoint receptor that is activated by proteins (PD-L1 and PD-L2) found on cancer and other immune cells.1 PD-L2 PD-L1 PD-1 TCR pMHCI PD-L2 PD-L1 Tumor cell Antigen - presenting cell 1. Sharpe AH, Pauken KE, Nat Rev Immunol 2018, 18:153-167 2. Natarajan A et.al. AACR 2022 3. Licensed from Cellectis 1 IOV-4001 TCR pMHCI PD-L2 PD-L1 Tumor cell PD-1 Inactivated T Cells Avoid Checkpoint Signals: PD-1 is inactivated using TALEN, restoring the ability of TIL cells to kill cancer cells.2,3 Cognate Antigen Cognate Antigen
Page 28
28 © 2026, Iovance Biotherapeutics, Inc. Phase 1/2 Open-Label First-in-Human Study: IOV-GM1-201 Endpoints • Phase 1: Safety (Complete) • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability Genetically Modified, PD-1 Inactivated TIL Therapy IOV-4001 in Previously Treated Metastatic Melanoma and NSCLC (NCT05361174) Cohort 1: Unresectable or metastatic melanoma Post-anti-PD-1/L1, post-BRAF/MEK inhibitor in patients with BRAF mutations Cohort 2: Stage III or IV NSCLC Post-anti-PD-1/L1 or post targeted therapy and either chemotherapy or anti-PD-1/L1 Patient Population Adults with unresectable or metastatic melanoma or advanced NSCLC N=53 N E X T- G E N E R A T I O N T I L T H E R A P Y : I O V- 4 0 0 1 Abbreviations: Anti-PD-1, anti-programmed cell death inhibitor; CR, complete response;; DCR, disease control rate; DOR, duration of response; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression free survival
Page 29
29 © 2026, Iovance Biotherapeutics, Inc. 29 © 2026, Iovance Biotherapeutics, Inc. IOV-3001: Next Generation IL-2 for TIL Supportive Regimen 1,2 Phase 1/2trial enrolling patients Recombinant fusion protein designed to enhance TIL survival and cellular proliferation • A modified copy of the coding sequence for aldesleukin (mdIL-2) is fused to a humanized monoclonal immunoglobulin (Ig)G1κ antibody • The mdIL-2 moiety of IOV-3001 binds to the IL-2-receptor (IL-2R) with subsequent phosphorylation of signal transducer and activator of transcription 5 (STAT5), resulting in enhanced performance 1. Mitra S, Leonard WJ, Journal of Leukocyte Biology 2018 103(4): 643-655 2. Simpson-Abelson M et al, ASCO 2024 Gene Expression: • Survival • Proliferation mdIL-2 IL-2R JAK1 P JAK3 STAT5 dimer Cytosol Nucleus P IOV-3001 IOV-3001 Heavy chain Light chain IOV-3001 Modified IL-2 (mdIL-2) TIL Antibody Preclinical data suggest IOV-3001 may have a better safety profile and require less frequent dosing compared to Proleukin
Page 30
30 © 2026, Iovance Biotherapeutics, Inc. IOV-5001: IL-12 TIL Therapy to Increase Efficacy 1. Zhang L, Rosenberg SA, et al, Clin Cancer Res 2015;21(10):2278–2288 2. Zhang L, Davis JS, et al, J Immunother Cancer 2020;8:e000210 3. Kobayashi M, Fitz L, et al, J Exp Med 1989;170:827–845. 4. Zeh HJ, Hurd S et al, J Immunother 1993;14:155–61. 5. Tugues S, Burkhard SH, et al, Cell Death and Differentiation 2015;22:237–246. 6. Cao X, Leonard K, et al, Cancer Res 2009;69:8700–9. 7. Steding CE, Wu S, et al, Immunology 2011;133:221–38. • Tethered IL-12 TIL cells can improve efficacy by remodeling the suppressive TME into an immuno- supportive state – In advanced melanoma patients, an ORR of 63% (n=16) was observed with prior generation IL-12 secreting TIL product at doses 10- to 100-fold lower than conventional TIL products1 • IL-12 shows independent clinical efficacy, with safe delivery to the TME being the primary challenge1,2 • Expression of IL-12 on IOV-5001 is induced upon antigen encounter in the TME1,2 • IOV-5001’s expressed IL-12 is tethered to the membrane surface of TIL to avoid release into circulation (shedding) 2 • Inducible IL-12 expression in the TME and lack of IL- 12 shedding are expected to allow increased IOV- 5001 cell doses and improved TIL efficacy in solid tumor cancers Abbreviations: IL-12, interleukin 12; MDSC, myeloid derived suppressor cell; NK, natural killer cell; NKT, natural killer T cel l; ORR, objective response rate; TME, tumor microenvironment; Treg, regulatory T cell NK and NK-T cell activation and proliferation3 CD8+ T cell activation and proliferation4 CD4+ T cell differentiation to Th15 Treg and MDSC downregulation6,7 30 Direct Action IFNγ Cytosol Nucleus TIL NFAT-TeIL-12 IL-12 IL-12R TCR Antigen © 2026, Iovance Biotherapeutics, Inc.
Page 31
31 © 2026, Iovance Biotherapeutics, Inc. 31 Corporate Summary
Page 32
32 © 2026, Iovance Biotherapeutics, Inc. 1. Includes anticipated revenue from Amtagvi® and Proleukin® and anticipated savings from strategic restructuring announced on August 7, 2025 2. Preferred shares are shown on an as-converted basis. Financial Position & Outlook Cash runwayinto Q3 2027 1 2025 Revenue (First Full Year of Launch) ~$264M FY25 Guidance of $250M-$300M Achieved Revenue Growth Margin Improvement Cost Control Cash position (12/31/25) $303M
Page 33
33 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Thank You